CIK 0001806952
- Non-accelerated filer
- Smaller reporting company
Lyell Immunopharma, Inc.
Sign in to watch- Ticker
- LYEL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 833006753
- Phone
- +1 650-695-0677
- Business address
- 201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080
- S-3 Offering Registration Statement
- 4 Open-market sale Chief Scientific Officer sold 129 shares at $15.93 ($2,055)
- 4 Open-market sale Chief Operating Officer sold 88 shares at $15.93 ($1,402)
- 4 Open-market sale President and CEO sold 545 shares at $15.93 ($8,682)
- 4 Open-market sale VP, Corporate Controller sold 416 shares at $15.93 ($6,627)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- 4 Open-market buy 10% owner bought 2,321,262 shares at $10.77 ($24,999,992)
- 4 Open-market buy 10% owner bought 2,321,262 shares at $10.77 ($24,999,992)
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 8-K Event Unregistered share sale
- 4 Open-market sale Chief Medical Officer sold 422 shares at $8.63 ($3,642)
- 4 Open-market sale Chief Medical Officer sold 500 shares at $12.70 ($6,350)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 8-K Event Other events
- 4 Open-market sale President and CEO sold 9,589 shares at $15.54 ($149,013)
- 4 Open-market sale Chief Operating Officer sold 989 shares at $15.54 ($15,369)
- 4 Open-market sale Chief Scientific Officer sold 1,457 shares at $15.54 ($22,642)
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
Page 1 of 19 · 365 filings